Tumor-infiltrating lymphocytes express vascular endothelial growth factor in renal cell carcinomas

Onkologie

Volumn 23, Issue 5, 2000, Pages 458-462

  Lummen G ^a   Blass Kampmann, S ^a   Rubben H ^a   Suhr, J ^a   Otto, T ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Renal cell carcinoma; Tumor infiltrating lymphocytes, TIL; Vascular endothelial growth factor, VEGF

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; VASCULOTROPIN;

ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; HOST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE SYSTEM; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; LYMPHOCYTE; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0033659471     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000027212     Document Type: Article

References (28)

1. Renal-cell carcinoma
2. Alpha-interferon improves survival in patients with metastatic renal carcinoma: Preliminary results of an MRC trial
3. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: Isolation, characterization, and anti-tumor activity
4. The immunotherapy and gene therapy of cancer
5. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor
6. + tumor-infiltrating lymphocytes in human renal cell carcinoma
7. HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer
8. Selective lysis of autologous tumor cells by recurrent γδ tumor-infiltrating lymphocytes from renal carcinoma
9. Lymphocytes infiltrating human prostate and bladder cancers express vascular endothelial growth factor, a potent vascular permeability and angiogenic factor
10. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: A potential role for T-cells in angiogenesis
11. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma
12. Vascular endothelial growth factor expression is increased in renal cell carcinoma
13. Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans
14. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2
15. Immunotherapy of metastatic renal cell carcinoma. Is clinical use justified with regard to efficacy, side effects and costs?
16. + T cells
17. T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor: A potential pathologic role
18. The role of vascular endothelial growth factor in blood vessel formation
19. Flow cytometric analysis of tumour-infiltrating lymphocytes in patients with renal cell carcinoma
20. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report
21. Immunotherapy of patients with advanced cancer using tumor infiltrating lymphocytes with or without recombinant interleukin-2 in human metastatic renal cell carcinoma
22. Adoptive immunotherapy for renal cell carcinoma using tumor infiltrating lymphocytes cultured in vitro with rIL-2, rhIL-4 and autologous tumor: A phase II trial
23. The immunological basis of adoptive cellular immunotherapy with tumor infiltrating lymphocyte in the treatment of metastatic renal cell carcinoma
24. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor
25. The in vitro effects of interleukin-12 upon tumor-infiltrating lymphocytes derived from renal cell carcinoma
26. Tumor reactivity of immune T cells in short-term culture
27. Variable expression of CD3-zeta chain in tumor-infiltrating lymphocytes (TIL) derived from renal cell carcinoma: Relationship with TIL phenotype and function
28. Adjuvant adoptive immunotherapy with tumor-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients